Risks and synergies from drug interactions

AIDS, Supplement

Volumn 10, Issue 1, 1996, Pages

  Sahai, Jan ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Drug interactions; HIV protease inhibitors; Nucleoside HIV reverse transcriptase inhibitors; Synergy; Toxicity

Indexed keywords

CYTOCHROME P450; DIDANOSINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

CONFERENCE PAPER; DRUG INTERACTION; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT;

ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0029803481     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. De Clercq E: Antiviral therapy for HIV infections. Clin Microb Ref 1995, 8:200-239.
2. Sahai J, Gallicano K, Pakuts A, et al.: Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994, 169:1103-1107.
3. Lee BL, Tauber MG, Sadler B, et al.: Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996, 59:14-21.
4. Sahai J: Avoiding the ciprofloxacin-didanosine interaction. Ann Intern Med 1995, 123:394-395.
5. Norbeck D, Kumar G, Marsh K, et al.: Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract LB-7].
6. McCrea JB: Indinavir (MK 639) drug interaction studies. XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.174].